Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer

被引：16

作者：

Strasser-Weippl, Kathrin ^{[1
]}

Badovinac-Crnjevic, Tanja ^{[2
,3
]}

Fan, Lei ^{[2
,3
]}

Goss, Paul E. ^{[2
,3
]}

机构：

[1] Wilhelminen Hosp, Ctr Oncol Hematol & Palliat Care, A-1160 Vienna, Austria

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[3] Harvard Univ, Sch Med, Boston, MA 02114 USA

来源：

BREAST | 2013年 / 22卷

关键词：

Extended treatment; Breast cancer; Endocrine; Adjuvant; TO-TREAT ANALYSIS; POSTMENOPAUSAL WOMEN; TAMOXIFEN THERAPY; RANDOMIZED-TRIAL; UPDATED FINDINGS; MA.17; TRIAL; LETROZOLE; EXEMESTANE; PREDICTION; OUTCOMES;

D O I：

10.1016/j.breast.2013.07.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A high ongoing recurrence rate in patients with endocrine responsive breast cancer provides the rationale for offering endocrine treatment for more than five years. The MA.17 study, comparing the aromatase inhibitor (AI) letrozole for five years after an initial five years of tamoxifen to no further treatment, provided the proof-of-principle for extended endocrine treatment. These results have meanwhile been confirmed by several other studies and an EBCTCG meta-analysis. More recently, data from the ATLAS trial, comparing 10 to five years of tamoxifen, have been published, similarly showing a benefit for longer endocrine treatment with tamoxifen. In postmenopausal women -including those who had been premenopausal at initial diagnosis - a cross-trial comparison of ATLAS and the AI studies indicates superiority of switching to letrozole versus ongoing tamoxifen, similar to superiority of the AIs over tamoxifen in the metastatic and early breast cancer settings. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：S171 / S175

页数：5

共 31 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis [J].

Amir, Eitan ;

Seruga, Bostjan ;

Niraula, Saroj ;

Carlsson, Lindsay ;

Ocana, Alberto .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) :1299-1309

[3] Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study [J].

Bartlett, John M. S. ;

Bloom, Kenneth J. ;

Piper, Tammy ;

Lawton, Thomas J. ;

van de Velde, Cornelis J. H. ;

Ross, Douglas T. ;

Ring, Brian Z. ;

Seitz, Robert S. ;

Beck, Rodney A. ;

Hasenburg, Annette ;

Kieback, Dirk ;

Putter, Hein ;

Markopoulos, Christos ;

Dirix, Luc ;

Seynaeve, Caroline ;

Rea, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :4477-4484

[4] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].

Coombes, R. C. ;

Kilburn, L. S. ;

Snowdon, C. F. ;

Paridaens, R. ;

Coleman, R. E. ;

Jones, S. E. ;

Jassem, J. ;

Van de Velde, C. J. H. ;

Delozier, T. ;

Alvarez, I. ;

Del Mastro, L. ;

Ortmann, O. ;

Diedrich, K. ;

Coates, A. S. ;

Bajetta, E. ;

Holmberg, S. B. ;

Dodwell, D. ;

Mickiewicz, E. ;

Andersen, J. ;

Lonning, P. E. ;

Cocconi, G. ;

Forbes, J. ;

Castiglione, M. ;

Stuart, N. ;

Stewart, A. ;

Fallowfield, L. J. ;

Bertelli, G. ;

Hall, E. ;

Bogle, R. G. ;

Carpentieri, M. ;

Colajori, E. ;

Subar, M. ;

Ireland, E. ;

Bliss, J. M. .

LANCET, 2007, 369 (9561) :559-570

[5] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J].

Davies, Christina ;

Pan, Hongchao ;

Godwin, Jon ;

Gray, Richard ;

Arriagada, Rodrigo ;

Raina, Vinod ;

Abraham, Mirta ;

Medeiros Alencar, Victor Hugo ;

Badran, Atef ;

Bonfill, Xavier ;

Bradbury, Joan ;

Clarke, Michael ;

Collins, Rory ;

Davis, Susan R. ;

Delmestri, Antonella ;

Forbes, John F. ;

Haddad, Peiman ;

Hou, Ming-Feng ;

Inbar, Moshe ;

Khaled, Hussein ;

Kielanowska, Joanna ;

Kwan, Wing-Hong ;

Mathew, Beela S. ;

Mittra, Indraneel ;

Mueller, Bettina ;

Nicolucci, Antonio ;

Peralta, Octavio ;

Pernas, Fany ;

Petruzelka, Lubos ;

Pienkowski, Tadeusz ;

Radhika, Ramachandran ;

Rajan, Balakrishnan ;

Rubach, Maryna T. ;

Tort, Sera ;

Urrutia, Gerard ;

Valentini, Miriam ;

Wang, Yaochen ;

Peto, Richard .

LANCET, 2013, 381 (9869) :805-816

[6] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen [J].

Dowsett, Mitch ;

Cuzick, Jack ;

Ingle, Jim ;

Coates, Alan ;

Forbes, John ;

Bliss, Judith ;

Buyse, Marc ;

Baum, Michael ;

Buzdar, Aman ;

Colleoni, Marco ;

Coombes, Charles ;

Snowdon, Claire ;

Gnant, Michael ;

Jakesz, Raimund ;

Kaufmann, Manfred ;

Boccardo, Francesco ;

Godwin, Jon ;

Davies, Christina ;

Peto, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :509-518

[7] Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J].

Fisher, B ;

Dignam, J ;

Bryant, J ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :684-690

[8] Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen [J].

Goss, Paul E. ;

Ingle, James N. ;

Pater, Joseph L. ;

Martino, Silvana ;

Robert, Nicholas J. ;

Muss, Hyman B. ;

Piccart, Martine J. ;

Castiglione, Monica ;

Shepherd, Lois E. ;

Pritchard, Kathleen I. ;

Livingston, Robert B. ;

Davidson, Nancy E. ;

Norton, Larry ;

Perez, Edith A. ;

Abrams, Jeffrey S. ;

Cameron, David A. ;

Palmer, Michael J. ;

Tu, Dongsheng .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1948-1955

[9] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[10] Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17 [J].